COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04454398

Mike Royal, MD

mroyal@sorrentotherapeutics.com

2020-07-01

Withdrawn

RCT

Randomized

Parallel

Blind label

unclear

Treatment

inclusion criteria: - evidence of moderate covid-19, diagnosed standard rt-pcr assay or equivalent testing - willing and able to comply with study procedures and follow-up visits - subject or family member/caregiver must have provided written informed consent which includes signing the institutional review board approved consent form prior to participating in any study related activity. however, if obtaining written informed consent is not possible, other procedures as provided in the march 27th, 2020 fda guidance on conduct of clinical trials of medical products during covid-19 pandemic, question 10, may be used.

- clinical signs indicative of severe covid-19 - rapidly progressive covid-19 which is likely to progress to "severe" within 24 hours - documented infection other than covid-19 - any medical condition that, in the investigator's opinion, could adversely impact safety - pregnant or lactating women - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit. note: participants who have been prescribed hydroxychloroquine or chloroquine with or without azithromycin or other approved products for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents so long as the dose remains stable. additionally, any approved or authorized treatment (e.g., remdesivir, dexamethasone or treatments approved under an emergency use authorization) is allowed.

2

Sorrento Therapeutics, Inc.

18

100

None

Severe disease at enrollment

6: Severe disease at enrollment

0

Incidence of serious adverse events (safety);All-cause mortality at 29 and 60 days;SARS-CoV-2 viral load as assessed using various sample types;Time to hospitalization, treatment, ICU admission, and discharge from ICU and/or hospital;Incidence of laboratory abnormalities (safety);Anti-drug antibodies;Incidence of adverse events (safety);Incidence of dose-limiting toxicities (safety);Incidence of treatment-emergent adverse events (safety);Cytokine levels

None

Phase 1

[{"arm_notes": "", "treatment_id": 1241, "treatment_name": "Sti-1499", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]